MDxHealth suspends 2026 revenue guidance after weak preliminary Q3

what happened

MDxHealth SA has preliminarily reported revenue from continuing operations for the third quarter of 2026, which ended September 30. According to a press release distributed by GlobeNewswire, revenue came in at about $22.7 million, the same as the restated third quarter of 2025 that excludes Resolve mdx, now treated as a discontinued operation. At the same time, the company suspended its 2026 revenue guidance of $110–115 million.

Tissue-based test volume (Confirm mdx and GPS mdx) totaled 11,232, down 11% year on year. Liquid-based volume (Exo mdx) rose to 11,792 from 4,600, but the prior-year base included Select mdx and Exo mdx, acquired in September 2025. Cash and equivalents stood at roughly $31.7 million as of September 30.

CEO Michael K. McGarrity said revenue fell short of expectations after unexpected turnover in the sales force, which followed the discontinuation of Resolve mdx. The company plans to detail its corrective actions with the full third-quarter results, with an earnings call set for November 12. The figures are preliminary, unaudited and subject to change.

why it matters

For investors, the key signals are the suspended annual guidance and the drop in tissue test volume, even though acquired assets helped support revenue. This adds uncertainty to the company's outlook until the full results and earnings call, so attention is likely to focus on how MDxHealth rebuilds its sales team.

tags

instruments